Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 26.
doi: 10.1097/MEG.0000000000003107. Online ahead of print.

Efficacy and safety of tenapanor in the management of irritable bowel syndrome with constipation: a systematic review and meta-analysis

Ahmed Aref  1 , Mohamed A Aldemerdash  2 , Islam Mohamed  3 , Abdallfatah Abdallfatah  4 , Hazem Abosheaishaa  5 , Ahmed Telbany  6 , Dushyant Singh Dahiya  7 , Hassan Ghoz  8 , Nikki Duong  9
Affiliations

Efficacy and safety of tenapanor in the management of irritable bowel syndrome with constipation: a systematic review and meta-analysis

Ahmed Aref et al. Eur J Gastroenterol Hepatol. .

Abstract

Introduction: Irritable bowel syndrome with constipation (IBS-C) is a common gastrointestinal disorder that significantly impacts quality of life. Tenapanor, a sodium/hydrogen exchanger inhibitor, shows promise in managing IBS-C. This systematic review and meta-analysis aim to evaluate the efficacy and safety of tenapanor 50 mg compared with placebo.

Methods: This systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A literature search was conducted on 7 October 2024 across PubMed, Cochrane, Embase, Scopus, and Web of Science databases. We included randomized controlled trials (RCTs) focusing on adult IBS-C patients aged 18-75. Quality assessment was performed using the risk of bias 2 tool. Primary outcomes included responder rates for abdominal symptoms (pain, discomfort, bloating, cramping, fullness) and complete spontaneous bowel movements (CSBM). Secondary outcomes comprised treatment-related adverse events (AEs) and those leading to treatment discontinuation. Data analysis was conducted using R software.

Results: Three RCTs involving 1378 patients were included. Tenapanor significantly improved symptoms versus placebo, including bloating [relative risk (RR) = 1.32; 95% confidence interval (CI), 1.15-1.51], cramping (RR = 1.27; CI, 1.13-1.44), discomfort (RR = 1.37; CI, 1.21-1.56), fullness (RR = 1.37; CI, 1.20-1.58), pain (RR = 1.37; CI, 1.17-1.49), and CSBM (RR = 1.54; CI, 1.24-1.91). However, tenapanor was associated with higher rates of treatment-related AEs (RR = 2.3; CI, 1.72-3.06) and AEs leading to discontinuation (RR = 9.08; CI, 3.63-22.71).

Conclusion: Tenapanor is effective in improving IBS-C symptoms but has a higher incidence of treatment-related AEs. Further studies are needed to evaluate its long-term safety.

Keywords: constipation; irritable bowel syndrome; tenapanor.

PubMed Disclaimer

References

    1. Palsson OS, Whitehead W, Törnblom H, Sperber AD, Simren M. Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology 2020; 158:1262–1273.e3.
    1. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. American Medical Association 2015; 313:949–958. doi: 10.1001/jama.2015.0954. - DOI
    1. Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol 2021; 116:17–44.
    1. Lacy BE, et al. Bowel disorders. Gastroenterology 2016; 150:1393–1407.e5.
    1. Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome. N Engl J Med 2017; 376:2566–2578.

LinkOut - more resources